What is the evidence for using subcutaneous apomorphine in nil by mouth Parkinson's patients in acute settings?
Subcutaneous apomorphine is an established intervention for managing "off" episodes and motor fluctuations in Parkinson's disease, though no direct studies on nil by mouth patients in acute settings were identified. The evidence supports its use due to rapid effectiveness and practicality in non-oral scenarios.
Authors
- Tripdatabase
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-13
- DOI
- https://doi.org/10.5281/zenodo.24192856
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00